JEFFREY G. KLEIN, P.A.
301 Yamato Road Suite 1240
Boca Raton, Florida 33431
Telephone: (561)953-1126 | Telefax: (561)994-6693 |
| Email: jklein@jkleinlegal.com |
November 5, 2015
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D. C. 20549
Attention: Ruairi Regan
Re:
CTT Pharmaceutical Holdings, Inc. f/k/a Mindesta Inc.
Amended Annual Report on Form 10-K
Filed October 8, 2015
File No. 000-30651
Dear Sir/Madam:
The following responses are filed in connection with the Commission’s comment letter dated October 20, 2015.
1. With respect to comment No. 1, the Company filed a Form 8-k with the Commission on November 3, 2015 providing the disclosure required by Item 4.02 of Form 8-K.
Request is hereby made that the Company be granted until November 18, 2015 to file its amended quarterly reports for the periods ended March 31, and June 30, 2015
Thanking you in advance for your cooperation in this matter.
Sincerely,
/s/Jeffrey G. Klein
Jeffrey G. Klein, counsel
CTT PHARMACEUTICAL HOLDINGS, INC.
(Stationary)
November 5, 2015
Securities and Exchange Commission
Washington, D.C. 20549
Re:
CTT Pharmaceutical Holdings, Inc.
Amended Annual Report on Form 10-K
Filed October 8, 2015
File No. 000-30651
Dear Sir/Madam:
The following is filed in connection with the comment letter dated October 20, 2015.
The undersigned, on behalf of CTT Pharmaceutical Holdings, Inc. acknowledges that:
·
The Company is responsible for the adequacy and accuracy of the disclosure in the filing.
·
Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filings; and
·
The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
/s/ Pankaj Modi
Pankaj Modi, Chief Executive Officer